LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
20 hedge funds and large institutions have $12.5M invested in LAVA Therapeutics in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
43% more funds holding
Funds holding: 14 → 20 (+6)
36% more capital invested
Capital invested by funds: $9.22M → $12.5M (+$3.3M)
7.89% less ownership
Funds ownership: 22.2% → 14.31% (-7.9%)
50% less call options, than puts
Call options by funds: $102K | Put options by funds: $203K
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$809K |
| 2 |
Walleye Capital
New York
|
+$340K |
| 3 |
Two Sigma Investments
New York
|
+$181K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$40.3K |
| 5 |
Two Sigma Advisers
New York
|
+$36.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.97M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.33M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$47.4K |
| 4 |
Morgan Stanley
New York
|
-$32.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.1K |
LVTX Hedge Fund Activity: Q1 2024 in Review
20 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q1 2024, worth a combined $12.5M — up 36% from $9.22M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LVTX positions and 5 closed out — a net gain of 6 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $809K. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $2.97M sold.
- 20 institutional investors held LAVA Therapeutics (LVTX) as of Q1 2024, up from 14 in Q4 2023.
- Funds reported $12.5M of LAVA Therapeutics stock for Q1 2024, up 36% quarter-over-quarter.
- 11 funds opened new LAVA Therapeutics positions in Q1 2024 and 5 closed out, a net change of +6 holders.
- The largest LAVA Therapeutics buyer in Q1 2024 was Sphera Funds Management, an estimated $809K added.
- The largest LAVA Therapeutics seller in Q1 2024 was Novo Holdings A/S, an estimated $2.97M sold.
Based on aggregated 13F filings for Q1 2024.